

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1617SXX

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 FEB 27 New STN AnaVist pricing effective March 1, 2006
NEWS 4 APR 04 STN AnaVist \$500 visualization usage credit offered
NEWS 5 MAY 10 CA/CAPLUS enhanced with 1900-1906 U.S. patent records
NEWS 6 MAY 11 KOREAPAT updates resume
NEWS 7 MAY 19 Derwent World Patents Index to be reloaded and enhanced
NEWS 8 MAY 30 IPC 8 Rolled-up Core codes added to CA/CAPLUS and
USPATFULL/USPAT2
NEWS 9 MAY 30 The F-Term thesaurus is now available in CA/CAPLUS
NEWS 10 JUN 02 The first reclassification of IPC codes now complete in
INPADOC
NEWS 11 JUN 26 TULSA/TULSA2 reloaded and enhanced with new search and
and display fields
NEWS 12 JUN 28 Price changes in full-text patent databases EPFULL and PCTFULL
NEWS 13 JUL 11 CHEMSAFE reloaded and enhanced
NEWS 14 JUL 14 FSTA enhanced with Japanese patents
NEWS 15 JUL 19 Coverage of Research Disclosure reinstated in DWPI
NEWS 16 AUG 09 INSPEC enhanced with 1898-1968 archive

NEWS EXPRESS JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 09:55:34 ON 24 AUG 2006

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 09:55:47 ON 24 AUG 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 22 AUG 2006 HIGHEST RN 903481-59-4
DICTIONARY FILE UPDATES: 22 AUG 2006 HIGHEST RN 903481-59-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> s loteprednol
L1 3 LOTEPRDNOL

=> d L1 1-3 str cn rn


L1 ANSWER 1 OF 3 REGISTRY COPYRIGHT 2006 ACS on STN
CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-
3-oxo-, chloromethyl ester, (11 β ,17 α)-, mixt. with
O-3-amino-3-deoxy- α -D-glucopyranosyl-(1 \rightarrow 6)-O-[2,6-diamino-
2,3,6-trideoxy- α -D-ribo-hexopyranosyl-(1 \rightarrow 4)]-2-deoxy-D-
streptamine (9CI) (CA INDEX NAME)

OTHER NAMES:

CN Loteprednol etabonate-tobramycin mixt.
RN 863983-05-5 REGISTRY


CM 1

Absolute stereochemistry.




CM 2

Absolute stereochemistry.



L1 ANSWER 2 OF 3 REGISTRY COPYRIGHT 2006 ACS on STN

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

CN Androsta-1,4-diene-17-carboxylic acid, 11,17-dihydroxy-3-oxo-,
chloromethyl ester, (11β,17α)- (9CI) (CA INDEX NAME)


OTHER NAMES:

CN Loteprednol

RN 129260-79-3 REGISTRY

L1 ANSWER 3 OF 3 REGISTRY COPYRIGHT 2006 ACS on STN

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

CN Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-3-oxo-, chloromethyl ester, (11 β ,17 α)- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN Alrex
CN CDDD 5604
CN HGP 1
CN Lenoxin
CN Lotemax
CN Loteprednol etabonate
CN P 5604
RN 82034-46-6 REGISTRY

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

11.34

11.55

FILE 'CAPLUS' ENTERED AT 09:57:00 ON 24 AUG 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Aug 2006 VOL 145 ISS 9

FILE LAST UPDATED: 23 Aug 2006 (20060823/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s L1

L2 132 L1

=> dup rem L2

PROCESSING COMPLETED FOR L2

L3 132 DUP REM L2 (0 DUPLICATES REMOVED)

=> e asthma

E1 1 ASTHIONALIDE/BI
E2 1 ASTHM/BI
E3 31996 --> ASTHMA/BI
E4 1 ASTHMA1/BI
E5 1 ASTHMA2/BI
E6 1 ASTHMAAND/BI
E7 5 ASTHMAGEN/BI
E8 5 ASTHMAGENIC/BI
E9 11 ASTHMAGENS/BI
E10 11 ASTHMALIKE/BI
E11 1 ASTHMAM/BI
E12 1 ASTHMAN/BI

=> s e3 or e7 or e8 or e10

31996 ASTHMA/BI
 21 ASTHMAS/BI
 32004 ASTHMA/BI
 ((ASTHMA OR ASTHMAS)/BI)
 5 ASTHMAGEN/BI
 11 ASTHMAGENS/BI
 13 ASTHMAGEN/BI
 ((ASTHMAGEN OR ASTHMAGENS)/BI)
 5 ASTHMAGENIC/BI
 11 ASTHMALIKE/BI

L4 32011 ASTHMA/BI OR ASTHMAGEN/BI OR ASTHMAGENIC/BI OR ASTHMALIKE/BI

=> s L2 and L4

L5 7 L2 AND L4

=> d 1-7 L5 ibib abs

L5 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:735068 CAPLUS

DOCUMENT NUMBER: 143:199889

TITLE: Combination of anticholinergics and glucocorticoids
 for the long-term treatment of asthma and
 COPD

INVENTOR(S): Goede, Joachim; Maus, Joachim; Cnota, Peter Jurgen;
 Szelenyi, Istvan

PATENT ASSIGNEE(S): Sofotec GmbH & Co. KG, Germany

SOURCE: U.S. Pat. Appl. Publ., 5 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005175548	A1	20050811	US 2005-51468	20050207
WO 2005074918	A1	20050818	WO 2005-EP652	20050124
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 2004-541956P P 20040206

AB The present invention describes a combination of topically inhaled medicinal formulations comprising an anticholinergic component and a glucocorticosteroid component and its use in the symptomatic and prophylactic treatment of diseases of the respiratory tract, especially with an obstructive component or underlying inflammation like asthma and chronic obstructive pulmonary disease (COPD). It further comprises the presentation of this combination in a locally applied (inhaled) formulation and application in an inhalation device for instance in the Novolizer.

L5 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:409325 CAPLUS

DOCUMENT NUMBER: 142:435859

TITLE: Soft steroid compositions for use in dry powder inhalants

INVENTOR(S): Goller, Michael I.; Li, Qi; Ly, Jade; Momin, Mohammed
 Nurul; Salas, Katherine; Ukeje, Anayo Michael;
 Yanamandra, Ramesh; Zeng, Xian-Ming
 PATENT ASSIGNEE(S): Ivax Corporation, USA; Norton Healthcare, Ltd.
 SOURCE: PCT Int. Appl., 41 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005041980	A1	20050512	WO 2004-US36477	20041103
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004285592	A1	20050512	AU 2004-285592	20041103
CA 2544422	AA	20050512	CA 2004-2544422	20041103
EP 1684767	A1	20060802	EP 2004-817524	20041103
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU				

PRIORITY APPLN. INFO.: US 2003-517324P P 20031103
 WO 2004-US36477 W 20041103

OTHER SOURCE(S): MARPAT 142:435859
 AB A method of producing a composition containing a soft steroid is disclosed.
 The

composition is suitable for administration via a dry powder inhalant. A blend consisted of 4.7 etiprednol dicloacetate and 95.3%by weight α -lactose monohydrate was prepared by mixing sieved particles.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:468794 CAPLUS

DOCUMENT NUMBER: 141:100057

TITLE: Possibilities in improvement of glucocorticoid treatments in asthma with special reference to loteprednol etabonate

AUTHOR(S): Szelenyi, I.; Hermann, R.; Petzold, U.; Pahl, A.; Hochhaus, G.

CORPORATE SOURCE: Institute for Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-University of Erlangen, Germany

SOURCE: Pharmazie (2004), 59(5), 409-411
 CODEN: PHARAT; ISSN: 0031-7144

PUBLISHER: Govi-Verlag Pharmazeutischer Verlag GmbH

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Allergic conditions contribute significantly to the burden of chronic disease in the industrialized world. The increasing prevalence has lead research into the discovery and development of various new therapeutic strategies. Despite considerable efforts of the pharmaceutical industry, the leukotriene antagonists were the only new class of asthma treatments to be licensed in the past 30 yr. Topical glucocorticoids

(GCs) are the most potent and effective therapy for treating allergic diseases. However, their use is limited by diverse undesired effects. Changes in pharmacokinetic parameters of GCs may be an interesting and promising approach to improve efficacy and safety of inhaled GCs. Loteprednol etabonate has been developed on the basis of the retrometabolic drug design. In animal studies, it has been demonstrated to have long-lasting anti-allergic (anti-asthmatic) effects without influencing the hypothalamic-pituitary axis (HPA). This soft steroid is now in phase III of the clin. development. Recently, loteprednol has been proven to be effective in the management of allergic rhinitis (400 µg once daily). No suppression of HPA was observed at clin. effective and higher doses. In conclusion, loteprednol as the first representative of soft steroids elicits marked anti-inflammatory effects, but has no impact on endocrine responses. It may represent a promising new therapy in the treatment of allergic rhinitis and asthma.

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:203704 CAPLUS

DOCUMENT NUMBER: 140:229455

TITLE: Combination of glucocorticoids and PDE-4-inhibitors for treating respiratory diseases, allergic diseases, asthma and COPD

INVENTOR(S): Locher, Mathias; Hermann, Robert

PATENT ASSIGNEE(S): Viatris G.m.b.H. & Co. K.-G., Germany

SOURCE: PCT Int. Appl., 26 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004019984	A1	20040311	WO 2003-EP8607	20030804
W: AU, BR, CA, CN, CO, CZ, GE, HR, ID, IL, IN, JP, KR, LT, LV, MD, MK, MX, NO, NZ, PL, SG, UA, US, UZ, YU, ZA				
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
CA 2492645	AA	20040311	CA 2003-2492645	20030804
AU 2003255365	A1	20040319	AU 2003-255365	20030804
EP 1526870	A1	20050504	EP 2003-790851	20030804
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, TR, BG, CZ, EE, HU, SK				
JP 2005539042	T2	20051222	JP 2004-531853	20030804
US 2005288265	A1	20051229	US 2005-523802	20050209
NO 2005001212	A	20050308	NO 2005-1212	20050308

PRIORITY APPLN. INFO.: DE 2002-10236688 A 20020809
WO 2003-EP8607 W 20030804

AB The invention relates to a novel combination of a glucocorticoid, especially loteprednol, and at least one phosphodiesterase-4 inhibitor (PDE-4-inhibitor), especially hydroxyindole-derivative

N-(3,5-dichloropyridine-4-yl)-2-[1-(4-fluorbenzyl)-5-hydroxyindole-3-yl]-2-oxoacetamide, for a simultaneous, sequential or sep. administration in the treatment of respiratory diseases, allergic diseases, asthma and chronic obstructive pulmonary diseases (COPD). Formulation of glucocorticoids and PDE-4-inhibitors can be prepared sep. and applied at the same time or at different times during the day; also combinations can be formulated.

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:832575 CAPLUS

DOCUMENT NUMBER: 137:346196

TITLE: Treatment of respiratory and lung diseases with antisense oligonucleotides and a bronchodilating agent

INVENTOR(S): Nyce, Jonathan W.; Li, Yukui; Sandrasagra, Anthony; Katz, Evan; Pabalan, Jonathan; Aguilar, Douglas; Miller, Shoreh; Tang, Lei; Shahabuddin, Syed

PATENT ASSIGNEE(S): Epigenesis Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 872 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002085308	A2	20021031	WO 2002-US13135	20020423
WO 2002085308	A3	20021219		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2002085308	A2	20021031	WO 2002-XA13135	20020423
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2002085308	A2	20021031	WO 2002-XB13135	20020423
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2002085308	A2	20021031	WO 2002-XC13135	20020423
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002256359	A1	20021105	AU 2002-256359	20020423
US 2004049022	A1	20040311	US 2003-627930	20030725
PRIORITY APPLN. INFO.:			US 2001-286137P	P 20010424
			WO 2002-US13135	A 20020423
			WO 2002-US13143	A2 20020423

OTHER SOURCE(S): MARPAT 137:346196

AB This patent relates to a composition comprising a carrier, oligonucleotides (oligos) that are antisense to adenosine receptors, and contain low amts. of or no adenosine (A), plus bronchodilating agents. All antisense oligonucleotides designed in accordance with the invention were highly effective at countering or reducing effects mediated by the receptors to which they are targeted. Two antisense phosphorothioated oligos targeting human adenosine A1 receptor mRNA, one targeting adenosine A2b receptor, and two targeting an A3 receptor are capable of countering the effect of exogenously administered adenosine which is mediated by the specific receptor they are targeted to. The activity of the antisense oligos are specific to the target and substitutively fail to inhibit another target. An oligonucleotide wherein the phosphodiester bonds are substituted with phosphorothioate bonds evidenced an unexpected superiority over the phosphodiester antisense oligo. In addition, they result in extremely low or non-existent deleterious side effects or toxicity. This represents 100% success in providing agents that are highly effective and specific in the treatment of bronchoconstriction and/or inflammation. Treatment with antisense oligonucleotides in combination with anti-inflammatory steroid and/or ubiquinones is also provided. These agents and the composition and formulations provided are suitable for the treatment of respiratory tract, pulmonary and malignant diseases associated with bronchoconstriction, respiratory tract inflammation and allergies, impaired airways, including lung disease and diseases whose secondary effects afflict the lungs of a subject, such as allergies, asthma, impeded respiration, allergic rhinitis, pain, cystic fibrosis, pulmonary fibrosis, RDA, COPD, and cancers, among others. The present agents and composition may be administered preventatively, prophylactically or therapeutically in conjunction with other therapies, or may be utilized as a substitute for therapies that have significant, neg. side effects. The method of the present invention is also practiced with antisense oligonucleotides targeted to many genes, mRNAs and their corresponding proteins in essential the same manner.

L5 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:385539 CAPLUS

DOCUMENT NUMBER: 137:346268

TITLE: Design and development of a soft corticosteroid, loteprednol etabonate

AUTHOR(S): Bodor, Nicholas; Buchwald, Peter

CORPORATE SOURCE: University of Florida, Gainesville, FL, USA

SOURCE: Lung Biology in Health and Disease (2002), 163(Inhaled Steroids in Asthma), 541-564
CODEN: LBHDD7; ISSN: 0362-3181

PUBLISHER: Marcel Dekker, Inc.

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review. Topical application of active corticosteroids that undergo nonoxidative, extrahepatic metabolism can provide improved, safer treatments of allergic diseases by minimizing the risk of systemic absorption and, therefore, the occurrence of side effects. Loteprednol etabonate, a soft corticosteroid that contains 17 α -carbonate and 17 β ester side chains and that was designed by using an inactive metabolite-based approach, lacks serious side effects and already received FDA approval for use in all inflammatory and allergy-related ophthalmic disorders. Since exptl. evidence indicates that it also produces strong and long-lasting antiinflammatory effect after intranasal or intrapulmonary administration, currently it is being developed for the treatment of allergic conditions, such as rhinitis and asthma.

REFERENCE COUNT: 89 THERE ARE 89 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:414694 CAPLUS

DOCUMENT NUMBER: 133:261550
 TITLE: Loteprednol etabonate: a soft steroid for the treatment of allergic diseases of the airways
 AUTHOR(S): Szelenyi, Istvan; Hochhaus, Gunther; Heer, Sabine; Kusters, Sabine; Marx, Degenhard; Poppe, Hildegard; Engel, Jurgen
 CORPORATE SOURCE: Pulmonary Pharmacology, Corporate Research & Development, ASTA Medica, Frankfurt and Dresden, Germany
 SOURCE: Drugs of Today (2000), 36(5), 313-320
 CODEN: MDACAP; ISSN: 0025-7656
 PUBLISHER: Prous Science
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: English

AB A review with 58 refs. There are several approaches for developing new antiallergic/antiasthmatic agents. One of them is the improvement of an existing class of effective drug classes. Due to some undesired effects of intranasal or inhaled corticosteroids, there is a need for better tolerated corticosteroids. Loteprednol etabonate belongs to the so-called class of soft steroids because it is metabolized by a 1-step reaction (hydrolysis) without using the cytochrome P 450 monooxygenase system. In in vitro investigations in human cells, loteprednol inhibited the release of proinflammatory cytokines (e.g., TNF- α , GM-CSF, IL-4, IL-5) to an extent according to its relative binding potency to the glucocorticoid receptor. In in vivo animal studies, loteprednol effectively inhibited allergically induced vascular leakage in the nasal cavity of actively sensitized Brown Norway rats and rhinorrhea in actively sensitized domestic pigs following nasal challenge. In several models of allergic asthma, loteprednol was able to suppress the allergically induced late-phase eosinophilia in mice, rats and guinea pigs. After intrapulmonary administration of loteprednol, only a slight, nonsignificant reduction in thymus weight was observed in a dose range far less than the therapeutically relevant doses. Its therapeutic ratio is clearly superior to those of beclomethasone and budesonide. Loteprednol is a safe steroid with an extremely wide range between therapeutic and side-effect-inducing doses. Its elimination profile, its pronounced binding to plasma protein and erythrocytes and its low oral bioavailability makes this drug highly suitable for nasal or pulmonary use.

REFERENCE COUNT: 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file medline embase biosis

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	31.58	43.13
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-5.25	-5.25

FILE 'MEDLINE' ENTERED AT 10:02:46 ON 24 AUG 2006

FILE 'EMBASE' ENTERED AT 10:02:46 ON 24 AUG 2006
 Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 10:02:46 ON 24 AUG 2006
 Copyright (c) 2006 The Thomson Corporation

=> s loteprednol or loteprednol etabonate
 L6 374 LOTEPRDNOL OR LOTEPRDNOL ETABONATE

```
=> s asthma
L7      253257 ASTHMA

=> s L6 and L7
L8      35 L6 AND L7

=> dup rem L8
PROCESSING COMPLETED FOR L8
L9      24 DUP REM L8 (11 DUPLICATES REMOVED)

=> s L9 and (AY <2001 or PRY<2001 or PY <2001)
'2001' NOT A VALID FIELD CODE
'2001' NOT A VALID FIELD CODE
  1 FILES SEARCHED...
'2001' NOT A VALID FIELD CODE
'2001' NOT A VALID FIELD CODE
'2001' NOT A VALID FIELD CODE
'2001' NOT A VALID FIELD CODE
L10     5 L9 AND (AY <2001 OR PRY<2001 OR PY <2001)

=> d 15 ibib abs
  5 ANSWERS ARE AVAILABLE.  SPECIFIED ANSWER NUMBER EXCEEDS ANSWER SET SIZE
The answer numbers requested are not in the answer set.
ENTER ANSWER NUMBER OR RANGE (1):1-5

L10 ANSWER 1 OF 5      MEDLINE on STN
ACCESSION NUMBER:      2003330589      MEDLINE
DOCUMENT NUMBER:       PubMed ID: 12861354
TITLE:                 Lofeprednol etabonate: a soft steroid
                        for the treatment of allergic diseases of the airways.
AUTHOR:                 Szelenyi I; Hochhaus G; Heer S; Kusters S; Marx D; Poppe H;
                        Engel J
CORPORATE SOURCE:       Pulmonary Pharmacology, Corporate Research & Development,
                        ASTA Medica, Frankfurt and Dresden, Germany.
SOURCE:                 Drugs of today (Barcelona, Spain : 1998), (2000
                        May) Vol. 36, No. 5, pp. 313-20.
                        Journal code: 101160518. ISSN: 1699-3993.
PUB. COUNTRY:           Spain
DOCUMENT TYPE:           Journal; Article; (JOURNAL ARTICLE)
LANGUAGE:               English
FILE SEGMENT:           NONMEDLINE; PUBMED-NOT-MEDLINE
ENTRY MONTH:            200310
ENTRY DATE:             Entered STN: 16 Jul 2003
                        Last Updated on STN: 25 Oct 2003
                        Entered Medline: 24 Oct 2003

AB  There are several approaches for developing new antiallergic/asthmatic
agents. One of them is the improvement of an existing class of effective
drug classes. Due to some undesired effects of intranasal or inhaled
corticosteroids, there is a need for better tolerated corticosteroids.
Lofeprednol etabonate belongs to the so-called class of
soft steroids because it is metabolized by a one-step reaction
(hydrolysis) without using the cytochrome P450 monooxygenase system. In
in vitro investigations using human cells, lofeprednol inhibited
the release of proinflammatory cytokines (e.g., TNF-alpha, GM-CSF, IL-4,
IL-5) according to its relative binding potency to the glucocorticoid
receptor. In in vivo animal studies, lofeprednol effectively
inhibited allergically induced vascular leakage in the nasal cavity of
actively sensitized Brown Norway rats and rhinorrhea in actively
sensitized domestic pigs following nasal challenge. In several models of
allergic asthma, it was clearly demonstrated that
lofeprednol was able to suppress the allergically induced late
phase eosinophilia in mice, rats and guinea pigs. After intrapulmonary
administration of lofeprednol, only a slight, statistically
nonsignificant reduction in thymus weight was observed in a dose range far
```

less than the therapeutically relevant doses. Its therapeutic ratio is clearly superior to those of beclomethasone and budesonide. Loteprednol is a safe steroid with an extremely wide range between therapeutic and side effect inducing doses. Its elimination profile, its pronounced binding to plasma protein and erythrocytes and the low oral bioavailability makes this drug highly suitable for nasal or pulmonary use.

L10 ANSWER 2 OF 5 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 1999314468 EMBASE
TITLE: Therapeutic potential of phosphodiesterase 4 inhibitors in allergic diseases.
AUTHOR: Crocker I.C.; Townley R.G.
CORPORATE SOURCE: Dr. R.G. Townley, Dept. of Medicine/Allergy Division, Creighton University, 2500 California Plaza, Omaha, NE 68178, United States
original SOURCE: Drugs of Today, (1999) Vol. 35, No. 7, pp. 519-535. . Refs: 137
ISSN: 0025-7656 CODEN: MDACAP
COUNTRY: Spain
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 026 Immunology, Serology and Transplantation
030 Pharmacology
037 Drug Literature Index
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 27 Sep 1999
Last Updated on STN: 27 Sep 1999

AB Cyclic adenosine monophosphate (cAMP) is thought to be associated with inflammatory cell activity: high levels tend to decrease proliferation and cytokine secretion, whereas low concentrations have the opposite effect (1). Since many phosphodiesterases (PDEs) degrade cAMP, inhibitors of this enzyme decrease inflammatory cell activity. Theophylline, which has nonselective PDE inhibitor activity in addition to its other mechanisms of action, has been used in the treatment of asthma for many years. Unfortunately, because of the important role of PDEs in the cell, nonspecific inhibition of these enzymes causes many undesirable side effects. The discovery of PDE isoenzyme families (PDE1-PDE10), their subtypes (HPDE4 and LPDE4) and their differential distribution among the cell types, as well as their specific functions in controlling cell processes, has led to the development of new, specific PDE4 inhibitors. This review details the rationale for the use of PDE4 inhibitors in the treatment of allergic disease. In addition, the effects of PDE4 inhibitors in vitro, in preclinical animal models and in the clinic are covered. Finally, up-to-date information on the most recently developed inhibitors, such as SB-207499, CDP-840, AWD-12-281 and D-4418, is provided.

L10 ANSWER 3 OF 5 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 1999273042 EMBASE
TITLE: The ideal steroid.
AUTHOR: Brattsand R.
CORPORATE SOURCE: R. Brattsand, Astra Draco AB, Preclinical R and D, PO Box 34, S-221 00 Lund, Sweden
SOURCE: Pulmonary Pharmacology and Therapeutics, (1999) Vol. 12, No. 2, pp. 119-122. . Refs: 19
ISSN: 1094-5539 CODEN: PPTHFJ
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; Conference Article
FILE SEGMENT: 015 Chest Diseases, Thoracic Surgery and Tuberculosis
030 Pharmacology

037 Drug Literature Index
LANGUAGE: English
ENTRY DATE: Entered STN: 19 Aug 1999
Last Updated on STN: 19 Aug 1999
DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L10 ANSWER 4 OF 5 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 1999218575 EMBASE
TITLE: Allergies: New treatment options and studies.
AUTHOR: Evans Y.
CORPORATE SOURCE: Y. Evans, Univ. of Mississippi Hosp./Clinics, Jackson, MS, United States
SOURCE: Drug Topics, (7 Jun 1999) Vol. 143, No. 11 SUPPL., pp. 10s-15s. .
ISSN: 0012-6616 CODEN: DGTNA7
COUNTRY: United States
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 006 Internal Medicine
015 Chest Diseases, Thoracic Surgery and Tuberculosis
026 Immunology, Serology and Transplantation
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 8 Jul 1999
Last Updated on STN: 8 Jul 1999

AB For years, antihistamines, decongestants, and corticosteroids have been the mainstay in treating allergic disorders. Today, the pharmacotherapy options are expanding, and more clinical trials are being conducted to determine the best treatments for the various allergic disorders. When chronic diseases, such as allergic disorders, affect one in five North Americans, it is important that pharmacists stay abreast of the treatment options that are available and under investigation.

L10 ANSWER 5 OF 5 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 1999056606 EMBASE
TITLE: New molecular entities approved in 1998.
SOURCE: Drug Topics, (1 Feb 1999) Vol. 143, No. 3, pp. 60-71. .
ISSN: 0012-6616 CODEN: DGTNA7
COUNTRY: United States
DOCUMENT TYPE: Journal; Note
FILE SEGMENT: 037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English
ENTRY DATE: Entered STN: 19 Mar 1999
Last Updated on STN: 19 Mar 1999
DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

=> FIL STNGUIDE
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
19.17	62.30

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-5.25

CA SUBSCRIBER PRICE

FILE 'STNGUIDE' ENTERED AT 10:08:43 ON 24 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE